Compounded Medication – Prescription Only

This product is a compounded injectable formulation containing LL-37 supplied in a sterile injectable vial and dispensed only pursuant to a valid prescription issued by a licensed healthcare provider. LL-37 is a synthetic peptide corresponding to a naturally occurring human cathelicidin peptide. In compounding practice, peptide formulations may be prescribed when a provider determines that individualized formulation or concentration considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription. This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, immune effects, antimicrobial activity, or expected clinical outcomes.

General Scientific Information (Non-Therapeutic)

LL-37 is referenced in scientific literature for its amino acid sequence and classification as a cationic peptide derived from the human cathelicidin family. Research has examined its biochemical characteristics and interactions in laboratory and controlled research environments. Descriptions of molecular structure or peptide classification are provided solely for general scientific context. No claims are made regarding safety, effectiveness, immune modulation, antimicrobial activity, or suitability for any particular condition.

Contraindications

LL-37 injection should not be used in individuals who have a known hypersensitivity or allergy to LL-37, peptide-based compounds, or any component of the compounded formulation; have experienced prior adverse reactions to injectable peptide preparations; or are unable to tolerate injectable therapies as determined by the prescribing healthcare provider. Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

Peptide-based injectable formulations may produce local or systemic reactions. Injectable administration should be performed only as prescribed and supervised by a licensed medical provider. Caution is advised in individuals with autoimmune or inflammatory conditions or those receiving medications that affect immune or inflammatory pathways. Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to receiving this compounded formulation.

Potential Side Effects

Reported side effects associated with injectable peptide formulations may include injection site reactions such as pain, redness, swelling, or irritation; headache; dizziness; nausea; fatigue; or flu-like symptoms. Serious adverse reactions are uncommon but may occur. Patients should seek immediate medical attention if they experience signs of a severe allergic reaction or unexpected systemic symptoms.